Drugs / Polyethylene Glycols
Polyethylene Glycols
also known as
Macrogol · BAY81-8430 · Forlax · Macrogol/electrolytes · PEG · polyethylene glycol · Sanipeg · Transipeg
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05920213 | Oct 2023 → Apr 2024 | hepatic encephalopathy | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05485103 | Sep 2022 → Jul 2024 | inflammatory bowel disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT05362227 | Nov 2019 → May 2021 | — | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 3 | NCT02980562 Comparator | May → Sep 2015 | colon adenoma | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05216328 Comparator | Dec 2022 → Jan 2027 expected | opioid-induced constipation | Amsterdam UMC, location VUmc | Recruiting | No outcome recorded |
| Phase 4 | NCT02977286 Background | Jan 2017 → Oct 2019 | constipation disorder | Tufts Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02956057 Comparator | Nov 2016 → May 2017 | — | Tomas Bata Hospital, Czech Republic | Completed | No outcome recorded |
| Phase 4 | NCT01810653 Comparator | Apr 2006 → Dec 2008 | constipation disorder | Bayer | Completed | No outcome recorded |
| — | NCT05570318 Background | Nov 2022 → Aug 2024 | constipation disorder | University of Aarhus | Completed | No outcome recorded |
| — | NCT06207721 Background | Oct 2022 → Dec 2023 | outlet dysfunction constipation | Delta University for Science and Technology | Completed | No outcome recorded |
| — | NCT03395548 Comparator | Aug 2017 → May 2020 | — | Medical University of Graz | Completed | No outcome recorded |
| — | NCT02371655 Background | Oct 2015 → Dec 2016 | colonic neoplasm | University of Roma La Sapienza | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-20 | Eisai Inc. | “MOVICOL® HD” Launched A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan eisai.com ↗ |
| 2018-11-29 | Eisai Inc. | MOVICOL® Launched in Japan The First Polyethylene Glycol Preparation for Chronic Constipation in Japan eisai.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyethylene Glycols | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02956057 ↗ |
| Known as | BAY81-8430 | “Macrogol (Transipeg, BAY81-8430)” NCT01810653 ↗ |
| Known as | Forlax | “Macrogol (Forlax)” NCT01810653 ↗ |
| Known as | Macrogol | “Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination” NCT02371655 ↗ |
| Known as | Macrogol/electrolytes | “Macrogol/electrolytes has been proven to be effective for OIC, but is sometimes perceived by patients as unpleasant due to its taste.” NCT05216328 ↗ |
| Known as | PEG | “what is the efficacy of adding on polyethylene glycol (PEG) in overt HE (Grade II and above) against the standard-of-care arm” NCT05920213 ↗ |
| Known as | polyethylene glycol | “The goal of this clinical trial is to compare the efficacy of L-ornithine L-aspartate and Polyethylene Glycol in Cirrhotic Patients with Overt Hepatic Encephalopathy.” NCT05920213 ↗ |
| Known as | Sanipeg | “Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination” NCT02371655 ↗ |
| Known as | Transipeg | “Macrogol (Transipeg, BAY81-8430)” NCT01810653 ↗ |
| Route | Oral | “Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination” NCT02371655 ↗ |